After 120 days of CER administration, 67% of mice with the K-Ras mutation developed pancreatic tumor (pancreatic ductal adenocarcinoma and/or undifferentiated/anaplastic carcinoma). Here, KRAS is linked to pancreatic ductal adenocarcinoma.